December 15, 2025 — United States
Dilon Technologies has received U.S. Food and Drug Administration (FDA) clearance for its MarginProbe® 2 system and officially launched the next-generation device in the U.S. market, marking a significant milestone in intraoperative breast cancer surgery technology. The approval positions MarginProbe® 2 as a new option for surgeons seeking real-time margin assessment during lumpectomy procedures, where achieving clear margins on the first operation remains a critical clinical challenge.
The FDA clearance was announced by Dilon Technologies on December 15, 2025, through a public release distributed via PR Newswire and Morningstar. According to the company, MarginProbe® 2 is designed to improve upon the performance, usability, and workflow integration of the original MarginProbe® system, which has been in clinical use for more than a decade in breast-conserving surgery.
Breast-conserving surgery (BCS), commonly referred to as lumpectomy, aims to remove malignant tissue while preserving as much healthy breast tissue as possible. However, one of the most persistent challenges in BCS is ensuring that no cancer cells remain at the edges, or “margins,” of the excised tissue.
Traditionally, margin status is determined postoperatively through pathology analysis, often days after surgery. If margins are found to be positive, patients may require a second operation. Nationally, re-excision rates following lumpectomy have historically ranged from 15% to over 25%, depending on tumor type, pathology protocols, and institutional practices.
MarginProbe® 2 is intended to address this gap by providing real-time intraoperative feedback, allowing surgeons to assess excised tissue margins during the initial procedure and, when necessary, remove additional tissue before closing the surgical site.
How MarginProbe® 2 Works
MarginProbe® 2 uses radiofrequency spectroscopy to analyze the dielectric properties of excised breast tissue. Cancerous tissue exhibits different electromagnetic characteristics than normal tissue, allowing the system to provide a binary result (positive or negative) for each assessed margin.
According to Dilon Technologies, MarginProbe® 2 incorporates:
• Improved detection algorithms
• Enhanced sensitivity across a broader range of tumor types
• A redesigned user interface optimized for operating room workflows
• Faster assessment times compared to earlier generations
The system is used on the excised specimen rather than directly on the patient, minimizing procedural disruption while delivering actionable information during surgery.
One of the most challenging diagnoses in breast-conserving surgery is ductal carcinoma in situ (DCIS), a non-invasive form of breast cancer that can be difficult to visualize and fully excise. DCIS is a major driver of re-excision surgeries due to its diffuse growth patterns and subtle margin involvement.
Dilon reports that MarginProbe® 2 demonstrates improved sensitivity in detecting DCIS at the margins, an advancement that may be particularly meaningful for surgeons treating early-stage and non-invasive breast cancers. While the company emphasizes that MarginProbe® 2 does not replace pathology, it is positioned as a complementary tool that enhances intraoperative decision-making.
Impact on Patients and Health Systems
From a patient perspective, avoiding a second surgery can have substantial benefits, including:
• Reduced physical and emotional stress
• Lower risk of surgical complications
• Faster progression to adjuvant therapies such as radiation or chemotherapy
• Improved cosmetic outcomes
For hospitals and ambulatory surgery centers, reducing re-excision rates can translate into:
• Lower overall costs of care
• Improved operating room efficiency
• Better utilization of surgical resources
• Higher patient satisfaction metrics
As value-based care models continue to evolve in the U.S., technologies that reduce repeat procedures are increasingly scrutinized for both clinical and economic impact.
Regulatory Path and FDA Clearance
MarginProbe® 2 received FDA clearance following clinical evaluation and regulatory review demonstrating substantial equivalence and safety for its intended use. While the FDA clearance allows commercial distribution in the U.S., adoption decisions remain at the discretion of individual institutions, surgeons, and value analysis committees.
The clearance underscores the FDA’s continued oversight of intraoperative diagnostic tools, particularly those that influence surgical decision-making in real time.
Commercial Launch and Market Outlook
With FDA clearance secured, Dilon Technologies has initiated a U.S. commercial rollout of MarginProbe® 2. The company plans to engage breast surgeons, surgical oncologists, and hospital leadership through direct sales efforts, clinical education, and conference participation.
